487 related articles for article (PubMed ID: 29246942)
1. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
2. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
3. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
4. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
6. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
Suhasini AN; Wang L; Holder KN; Lin AP; Bhatnagar H; Kim SW; Moritz AW; Aguiar RCT
Leukemia; 2016 Mar; 30(3):617-626. PubMed ID: 26503641
[TBL] [Abstract][Full Text] [Related]
7. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Burke RT; Meadows S; Loriaux MM; Currie KS; Mitchell SA; Maciejewski P; Clarke AS; Dipaolo JA; Druker BJ; Lannutti BJ; Spurgeon SE
Oncotarget; 2014 Feb; 5(4):908-15. PubMed ID: 24659719
[TBL] [Abstract][Full Text] [Related]
8. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Krause G; Hassenrück F; Hallek M
Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
[TBL] [Abstract][Full Text] [Related]
9. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
10. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
McCaig AM; Cosimo E; Leach MT; Michie AM
Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
[TBL] [Abstract][Full Text] [Related]
12. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
13. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Compagno M; Wang Q; Pighi C; Cheong TC; Meng FL; Poggio T; Yeap LS; Karaca E; Blasco RB; Langellotto F; Ambrogio C; Voena C; Wiestner A; Kasar SN; Brown JR; Sun J; Wu CJ; Gostissa M; Alt FW; Chiarle R
Nature; 2017 Feb; 542(7642):489-493. PubMed ID: 28199309
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
17. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
18. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
[TBL] [Abstract][Full Text] [Related]
20. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]